We are excited to share with you that #CBPartners is joining @TrinityLifeSci - find out more in our latest press release: https://t.co/jZpgS2LhDf

https://t.co/Bk9p5og0gf - Could the real-world study of Pear Therapeutics' reSET-O prescription #digitaltherapeutic (#DTx) for opioid use disorder (OUD) be the start of proving DTx efficacy and downstream cost offsets for the treatment?

https://t.co/EG4e3eeNLo - Since the landmark decision by the FDA to amend #insulin and certain other biologic drugs to a different regulatory pathway, discover how the USA compares to Europe with insulin product list pricing. #biosimilars

Discover the evolving price and market access dynamics in the cell and gene therapy space. #pharma #biopharma #healthcare

In a recent education business partnership with @InspireEBP, a panel of consultants volunteered to take part in a virtual work experience project which tasked students with a market access business case. Find out about the experience here: https://t.co/dGfy11aZsx

https://t.co/GNU2HiTBgR - Explore what factors should be considered when assessing and communicating the value of non-curative cell and gene therapies to payers to maximize access. #healthcare #pharma #celltherapy #GeneTherapy

https://t.co/EyEbfpsTyx - Discover the top #healthcare policy priorities from the SPD who won the most votes in Sunday’s German election, as well as the potential outlook of a three-party coalition. #CBPinfogram #Election2021 #pharma

#PaigeProstate, the first #AI based software designed to identify areas of concern on a #prostatecancer biopsy image, is granted FDA approval through the #denovopathway https://t.co/lo3fchP4qC #marketacces #digitalpathology

Will the launch Walmart and Novo Nordisk’s low-cost brand insulin, ReliOn, achieve the promised benefit of widespread change and improved care for patients in the long run? https://t.co/SgvKkc3cZW #healthcare #healthcaretrends #health #diabetes

The #healthcare sector is becoming increasingly attractive to non-traditional players as they take their chance in entering the field. Discover part one in a two-part series which focuses on the successes & failures of four companies.

#CBPartners investigates the impact that the #COVID19 pandemic has had on the #UShealthcare system over the past 18 months, with a focus on: patients and providers, reimbursement, clinical research, and distribution https://t.co/F4d2c76ED6

#Verily further establishes its presence in the #digitaltherapeutics space with the announcement of its first major acquisition of software platform, #SignalPath – #CBPartners explains how this could elevate #clinicalresearch https://t.co/7TDMSwJbQZ

Following on from a recent article investigating #marketaccess opportunities for rare disease products in #China, #CBPartners’ Asia-Pacific Center of Excellence analyzes the opportunities that lie ahead for #oncology products #NRDL https://t.co/M94mgNsX8V

A recent study of the review of new medicines by #regulatory and #HTA bodies highlights inefficiencies in the pathway to patient access https://t.co/E9K85HQthO

#CBPartners’ Asia-Pacific Center of Excellence analyzes the #marketaccess opportunities that lie ahead for rare disease products in #China based upon 2020 #NRDL inclusions https://t.co/kn6MC2EQV9

To create & sustain meaningful, mutually rewarding collaborations with organizations within CBPartners’ local communities, cbpGIVES recently partnered with NY based social venture Local Civics to develop a ‘Healthcare Career Exposure’ workshop series.

The biosimilar landscape is witnessing a boom across countries in the EU, Latin America and Asia at the forefront of the expanding #biosimilar market. CBPartners’ regional experts provide expert insights into the trends & dynamics in this #podcast.

Discover insights into the commercial opportunity for #drug products in #China, based on research into the dynamics of products listed on China’s 2017 #NRDL, & subsequent sales data. https://t.co/D0wvKOYNfX #AsiaPacific

#Japan has formally introduced cost-effectiveness assessments (CEAs) to calculate post-listing price adjustments for products which exceed specific sales thresholds (>¥5bn peak sales). Find out about two products that have completed the CEAs #CBPinfogram

https://t.co/APTtQ0B8Ay - COVID-19 #VaccinePassports are an emerging #digital health innovation which will provide a platform where traveler health data concerning #COVID19 testing & vaccination records can be centralized for screening upon arrival at a country or event.